Walmart Slides Most Since 2022 on Slowing US Sales Growth

Walmart reported earnings that missed analyst expectations, with pharmaceutical sales declining due to federal price negotiations on drug costs, according to Bloomberg analyst Poonam Goyal. Goyal said the pharmaceutical sales impact is expected to continue affecting results. Walmart's US comparable sales growth has slowed, and the company may address investor concerns by emphasizing competitive pricing to attract customers.

Next story